Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24668088 | 0.93 | TLR4 (0.59) | TLR4TRPV1 | |
| SCHEMBL26422869 | 0.93 | TLR4 (0.61) | TLR4TRPV1 | |
| SCHEMBL26418227 | 0.90 | TLR4 (0.49) | TLR4 | |
| SCHEMBL26418211 | 0.87 | TLR4 (0.56) | TLR4TRPV1 | |
| SCHEMBL24668068 | 0.86 | TLR4 (0.56) | TLR4TRPV1 | |
| SCHEMBL26446125 | 0.85 | TLR4 (0.44) | TLR4 | |
| SCHEMBL871909 | 0.85 | TLR4 (0.61) | TLR4 | |
| SCHEMBL23417719 | 0.84 | TLR4 (0.62) | TLR4TRPV1 | |
| SCHEMBL23417790 | 0.83 | TLR4 (0.49) | TLR4 | |
| SCHEMBL26422997 | 0.82 | TLR4 (0.51) | TLR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238436-A1 | COMPOSITIONS INCLUDING CONJUGATED THERAPY ENHANCERS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-07-18 | — | — | US | disclosed |
| US-20230128688-A1 | DIRECTED CONJUGATION TECHNOLOGIES | KLEO PHARMACEUTICALS, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230128688-A1 | DIRECTED CONJUGATION TECHNOLOGIES | KLEO PHARMACEUTICALS, INC. | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230128688-A1 | DIRECTED CONJUGATION TECHNOLOGIES | CD2BP2, CD2, CD47 | TLR4 3806/4885TRPV1 4868/4885 |
| US-20240238436-A1 | COMPOSITIONS INCLUDING CONJUGATED THERAPY ENHANCERS | LGMN, LPXN, LY96 | TLR4 289/4885TRPV1 4734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.